Apple wins $250 in Masimo smartwatch patent case
But the company says its ultimate goal wasn't money, but to get an injunction.
The legal battle between Apple and medical technology company Masimo rages on, with the bigger company — sorta, kinda — winning their latest face off. A federal jury has agreed with Apple that previous versions of Masimo's W1 and Freedom (pictured above) watches infringed on its design patents, according to Reuters. It only awarded Apple $250 in damages, which is the smallest amount that could be awarded for patent infringement, but the company's lawyers reportedly told the court that it wasn't after money anyway.
What Apple, which is worth $3.5 trillion, wanted was an injunction on the sales of Masimo's current smartwatch models. However, the jury determined that those newer models don't violate Apple's intellectual property. That is why Masimo is also treating the jury's decision as a win, telling the news organization that it's thankful for the verdict that's "in favor of Masimo and against Apple on nearly all issues." Apparently, the ruling only affects a "discontinued module and charger." As for Apple, it told Reuters that it was "glad the jury's decision today will protect the innovations [it advances] on behalf of [its] customers."
Masimo sued Apple in 2021, accusing it of infringing on several of its light-based blood-oxygen monitoring patents, while the tech giant countersued a year later. A court sided with Masimo in 2023, forcing Apple to pause sales on its latest smartwatch models, as the US International Trade Commission blocked all Watch Series 9 and Ultra 2 imports into the country. The company appealed and was ultimately able to sell its watches in the country earlier this year by removing the technology from the units offered in the US.
